ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy

Article

Abstract

Objective

The aim of this study was to evaluate the effect of the excision repair cross-complementing (ERCC1) expression on survival in advanced gastric cancer patients who underwent surgical resection and treated with oxaliplatinbased adjuvant chemotherapy.

Methods

Sixty-three patients who underwent surgical resection for cure and treated with oxaliplatin-based adjuvant chemotherapy were included in this study. The expressions of ERCC1 of gastric cancer were examined by immunohistochemistry and the patients were categorized into ERCC1-(+) and ERCC1-(-) groups. The relation between ERCC1 expression and survival of patients was examined.

Results

Of the 63 eligible patients, 36 patients (57.1%) had tumor with a positive expression of ERCC1 and the remaining 27 patients had tumor with a negative ERCC1 expression. Expression differences of ERCC1 didn’t correlated with age (P = 0.827), gender (P = 0.12), differentiation (P = 0.113), histological type (P = 0.942), site of tumor (P = 0.221), size of tumor (P = 0.608), stage (P = 0.815) and lymphatic invasion (P = 0.165). Overall survival (OS) was significantly longer in patients without ERCC1 expression, when compared to patients with ERCC1 expression (P = 0.023). Multivariate analysis revealed that ERCC1 expression significantly impacted on OS (HR: 4.049; P = 0.000).

Conclusion

We concluded that resected and treated with oxaliplatin-based adjuvant chemotherapy gastric cancer patients without ERCC1 expression have a better survival when compared to patients with ERCC1 expression. ERCC1 expression will hopefully provide a rational basis for improving adjuvant chemotherapeutic strategies for gastric cancer patients. ERCC1, itself, may be a prognostic factor for gastric cancer.

Key words

adjuvant chemotherapy oxaliplatin ERCC1 gastric cancer survival 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin 1. Gastroenterol, 2006, 20: 633–649.CrossRefGoogle Scholar
  2. 2.
    Li GC, Zhang YL, Zhang M. An analysis of global cancer incidence and mortality trendency from 1999 to 2002. Bull Chin Cancer (Chinese), 2008, 8: 646–649.Google Scholar
  3. 3.
    Yang L, Li LD, Chen YD, et al. Cancer incidence and mortality estimates and prediction for year 2000 and 2005 in China. Chin J Health Stat (Chinese), 2005, 4: 218–221.Google Scholar
  4. 4.
    Paoletti X, Oba K, Burzykowski T, et al. Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis. JAMA, 2010, 303: 1729–1737.PubMedCrossRefGoogle Scholar
  5. 5.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006, 355: 11–20.PubMedCrossRefGoogle Scholar
  6. 6.
    Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg, 2009, 96: 26–33.PubMedCrossRefGoogle Scholar
  7. 7.
    Broxterman HJ, Gotink KJ, Verheul HM. Understanding the causes of multidrug resistance in cancer: acomparison of doxorubicin and sunitinib. Drug Resist Updat, 2009, 12: 114–126.PubMedCrossRefGoogle Scholar
  8. 8.
    Wei J, Zou Z, Qian X, et al. ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer, 2008, 98: 1398–1402.PubMedCrossRefGoogle Scholar
  9. 9.
    Ota S, Ishii G, Goto K, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009; 64: 98–104.PubMedCrossRefGoogle Scholar
  10. 10.
    Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res, 2005, 11: 2215–2221.PubMedCrossRefGoogle Scholar
  11. 11.
    Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall- cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 2006, 355: 983–991.PubMedCrossRefGoogle Scholar
  12. 12.
    Kwon HC, Roh MS, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol, 2007, 18: 504–509.PubMedCrossRefGoogle Scholar
  13. 13.
    Bramson J, Panasci LC. Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res, 1993, 53: 3237–3240.PubMedGoogle Scholar
  14. 14.
    Matsubara J, Nishina T, Yamada Y, et al. Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer, 2008, 98: 832–839.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  • Qiang Li
    • 1
  • Chengxue Dang
    • 1
  • Zhigang Liu
    • 1
  • Ruifang Sun
    • 1
  1. 1.Department of Oncologic Surgery the First Affiliated HospitalMedical school of Xi’an Jiaotong UniversityXi’anChina

Personalised recommendations